What is Leerink Partnrs’ Estimate for Immunic Q1 Earnings?

Immunic, Inc. (NASDAQ:IMUX) – Equities research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Immunic in a note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will earn ($0.25) per share for the quarter, down from their previous estimate of ($0.22). The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic’s Q2 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.71) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.53) EPS and FY2026 earnings at ($0.53) EPS.

Other analysts have also recently issued reports about the stock. D. Boral Capital restated a “buy” rating and set a $17.00 price target on shares of Immunic in a report on Tuesday. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. William Blair assumed coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Stock Down 5.2 %

Shares of NASDAQ:IMUX opened at $1.00 on Friday. The company has a market cap of $89.70 million, a P/E ratio of -0.81 and a beta of 1.91. The company’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.20. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11.

Institutional Investors Weigh In On Immunic

A number of large investors have recently bought and sold shares of IMUX. Jane Street Group LLC lifted its position in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. HB Wealth Management LLC bought a new position in shares of Immunic in the 4th quarter valued at approximately $81,000. State Street Corp raised its stake in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. Virtu Financial LLC acquired a new stake in Immunic in the 3rd quarter worth approximately $50,000. Finally, Millennium Management LLC boosted its position in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares during the period. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.